Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
Sunday, August 14, 2022 11:36:22 PM
Your response to Q1/Q2 answered my question.
I was aware however of Gilead Sciences acquiring Kite for $11.9 B in 2017 if I remember the year correctly.
Thank you again for your reply and valuable input.
My only other question is do you perceive that Kite's mRNA Vaccine IP is based on the same NR2F6 Checkpoint inhibitor that RGBP's is based on, or is it a variation of it like Eli Lilly's. My understanding is that Eli Lilly & RGBP share common IP claim to NR2F6 but the molecule the !P is based on is not 100% identical. Is this the case with Kite's mRNA Cancer Vaccine IP? I have not been able to locate this specific information.
Your take on this would be much appreciated.
Best regards
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM